Clinical Trial Update: Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating icotinib as second-line treatment in esophageal carcinoma/esophagogastric junction adenocarcinoma with EGFR overexpression or positive …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Gastroesophageal Junction
• Esophageal Carcinoma

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Adenocarcinoma of the Gastroesophageal Junction, Esophageal Carcinoma | Phase 2 | Status: COMPLETED